Business
Virax Biolabs Announces NASDAQ Closing Bell Ringing to Celebrate Initial Public Offering
LONDON, Aug. 16, 2022 /PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention,
About this update from Virax Biolabs Group Limited
[{"type":"text","content":"LONDON, Aug. 16, 2022 /PRNewswire/ -- Virax Biolabs (\"Virax\" or the \"Company\") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, today announced that Chairman of the Board and Chief Executive Officer, James Foster will ring the Nasdaq Stock Market closing bell on Thursday, August 18, 2022. This comes after Virax began listing its common shares on the Nasdaq Capital Market on July 21, 2022.\n\n \n \n \n \n \n \n\n \nThe ceremony will begin at approximately 3:45 p.m. ET on August 18 and can be viewed live at https://www.nasdaq.com/marketsite/bell-ringing-ceremony.\n\"I am honored to ring the Nasdaq closing bell on behalf of the Virax team,\" commented James Foster. \"The bell ringing ceremony is a great opportunity to celebrate the major milestone of the Company going public, and is representative of opening a new era for Virax. I am grateful to be joined by my talented team of colleagues and those who have supported us through all the stages of Virax's development over the years. Supported by our major progress and key strategic partnerships since the start of 2022, I am confident and excited for Virax's journey ahead.\"\nAbout Virax Biolabs Group LimitedFounded in 2013, Virax Biolabs Group Limited is an innovative biotechnology group focused on the detection and diagnosis of viral diseases, with a particular interest in the field of immunology.\nVirax Biolabs Group Limited is currently developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus. For more information, please visit www.viraxbiolabs.com. \nSafe Harbor StatementThis press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance...